RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS

Marbofloxacin is one of fluoroquinolones developed exclusively for veterinary medicine. The primary aim of the study is to identify and to assess the evidence which relates to the clinical efficacy of marbofloxacin in the treatment of urinary tract infections in small animal practice. 118 dogs and 123 cats were referred to Internal Medicine Department Polyclinics with lower urinary tract symptoms whom hadn't received antimicrobial or anti‐inflammatory therapy previous 15 days, were included in the study. The diagnosis was confirmed by clinical findings, urinalysis and imaging. Rectal temperature, appetite, urinary signs and pain on abdominal palpation were monitored at two visits (day 0 and day 14). The timetable depending on diagnosis: two urinalyses and two bacterial examinations and antibacterial susceptibility testing per case were performed. Bacterial UTI were confirmed of 36 dogs and 28 cats. Urine samples were collected on the first referral demonstrated the presence of various bacteria with a marked predominance of P. mirabilis and coagulase positive Staphylococci in canine and feline urine samples, respectively. Antimicrobial susceptibility test results revealed 25 (65.7%) of dog isolates and 24 (85.7%) of cat isolates were susceptible to marbofloxacin. Treatment of UTIs is generally challenging for the small animal practitioner. Because of long‐term antimicrobial usage necessity, especially bacterial culture and susceptibility test are very important for treatment success. Marbofloxacin usage can be rewarding in the treatment of UTIs in dogs and cats. Thus, revealed the current status of Turkey for the first time. Key Words: antimicrobials; cat; dog; marbofloxacin; urinary tract infection